Oncotarget, an English language journal, began in the year 2010, is a medical journal which covers studies on oncology (a branch of medicine dealing with the diagnosis, treatment, and prevention of cancer). The journal focuses on oncology in all aspects including improvement of the management methods of cancer patients, all causes of all types of cancer and its treatments. It also concentrates on the importance and outcome of new and current therapies. The publication has also gone deeper into publishing papers in other fields such as immunology, age-related diseases, pathology, and Endocrinology mainly due to the complexity of tumor development.
Oncotarget has its editors-in-chief as Mikhail Blagoskolonny, a scientist studying cancer and Andrei Gudkov. Oncotarget is indexed in PubMed and PubMed Central, Science Citation Index Expanded, BIOSIS Previews among others. It was also previously indexed in Index Medicus until the year 2017. Oncotarget reviews studies made on cancer such as one made on 15th Dec 2015. The investigation showed that tumors are made up of different molecular subtypes thus incompatible molecular portraits can be found in various parts of the same tumor when sampled. The study involved finding out the impact on downstream kinase substrate, and the activation of FDA approved drug targets that may be caused by the difference in the molecular subtypes of tumor.
According to the study, the materials used were two independent sets of livers which underwent metastases after the primary bowel cancer attacked. The methods employed were reverse phase protein array and laser capture micro dissection which were used to assess signaling networks driven by protein-kinase. Results of the study showed that activation of the protein kinase B(AKT-mTOR) and Mitogen-activated protein kinase (MAPK) pathways were maintained by several areas of the same biopsy. The study concluded that an area of the tumor offers independent protein pathway activation energy from another part of the same tumor. This means a high percentage of the tumor cell population could activate a dominant protein pathway network. The study gave an indication that along with protein signaling measurements, a genomic analysis should as well be used to get the precise analysis.